Clinical trial · Observational
ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
Circulating Tumor DNA-based Minimal Residual Disease (MRD) Assessment in Local Advanced Esophageal Squamous Cell Carcinoma Treated by Definitive Concurrent Chemoradiotherapy
NCT05426850CI-TRIAL-00059216unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To analyze the relationship between the dynamic changes of circulating tumor DNA (ctDNA) and tumor relapse of esophageal squamous cell carcinoma treated by concurrent chemoradiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- ctDNA(+) Cohort
- description
- ctDNA(+) Cohort in pretreatment and posttreatment plasma samples was defined by accessing the presence of one or more mutations identified in match tumor samples.
- label
- ctDNA(-) Cohort
- description
- ctDNA(-) Cohort in pretreatment and posttreatment plasma samples was defined by the absence of one or more mutations identified in match tumor samples.
Primary outcomes (1)
- measure
- Relationship between ctDNA status after chemoradiotherapy and relapse.
- timeFrame
- ctDNA will be tested within 1 year after chemoradiotherapy
- description
- To assess if recurrent esophageal cancer is detectable earlier by ctDNA positive in plasma.
Secondary outcomes (4)
- measure
- Changes of ctDNA status.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. 18-75 years old. 2. ECOG 0-1. 3. Esophageal squamous cell carcinoma confirmed by pathology. 4. No radiotherapy, chemotherapy, or other treatments prior to enrollment. 5. Locally advanced esophageal squamous cell carcinoma (II-IVa, IVB with supraclavicular lymph node metastasis). 6. No severe abnormal hematopoietic, cardiac, pulmonary, renal, hepatic function, or immunodeficiency. 7. Informed consent signed. Exclusion Criteria: 1. Less than 50.4Gy/28fx of radiotherapy dose. 2. Without Concurrent chemotherapy. 3. Pregnant or breastfeeding women or fertile patients who refused to use contraceptives.
References
Publications (0)
Data not yet available
No reference posted for this study.